Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100199 · ClinicalTrials.gov registry record · Phase 2
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT05100199 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 328 participants.
The verdict
NCT05100199, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL.
Interventions
- DRUG Placebo
- DRUG OnabotulinumtoxinA X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05100199
The ClinicalTrials.gov registry entry for NCT05100199 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05100199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05100199 about?
NCT05100199 is a clinical study titled "A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines". This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL.
What is the current status of trial NCT05100199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2021-10-06. Estimated completion is 2022-12-02.
What interventions are being tested in trial NCT05100199?
The interventions under investigation include: Placebo (DRUG), OnabotulinumtoxinA X (DRUG).
Who is sponsoring clinical trial NCT05100199?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.